Clinical trials
for patients

The purpose of this study is to learn more about the effectiveness and safety of the study drug, volrustomig (also known as MEDI5752), when given in combination with a standard treatment for colorectal cancer.

The purpose of this study is to determine the highest dose of BI 3819026 that people with advanced cancer can tolerate when taken alone and in combination with ezabenlimab.

The trial consists of 3 parts. The objective of Part 1 is to assess the safety of GEN1079 at increasing doses and to identify the doses to be used in subsequent phases. The objective of Part 2 is to refine and identify the dose that is effective while causing the fewest side effects. The goal of Part 3 is to further investigate whether GEN1079 works against the tumor and how it does so, and to continue learning about its side effects.

The goal is to continuously monitor your well-being and safety, and to ask you if you have started a new treatment. If, for any reason, the doctor or trial staff are unable to contact you, a family member may provide information about your condition, or the trial doctor may obtain it from sources such as your medical records, national or local registries, or publicly available information, as permitted by local regulations.

The main objective of this study is to compare disease-free survival (DFS) between patients receiving TAR-210 and investigator-selected intravesical chemotherapy.

The main objective is to evaluate the safety and tolerability of IMC-P115C as monotherapy and in combination in participants with PRAME-positive advanced tumors, and to identify the MTD (maximum tolerated dose) and dosing regimens (combination of IMC-P115C dose, dosing frequency, and premedication) for further optimization.

The main objective of this trial is to assess the efficacy or antitumor effect of a virus called DNX-2401 in patients with high-grade brain tumors that have relapsed or progressed after standard treatment.

The objective of the study is to evaluate the efficacy and safety of IV BCV versus IV CDV in patients with adenovirus viremia after allogeneic HCT.

The objective of the study is to investigate the long-term effects of treatment with AAA617 in patients who received it for their prostate cancer. The Study Physician will focus on known or potential long-term side effects. Safety assessments will be performed for up to 10 years, starting from the first dose of AAA617 in the previous treatment study.

The objective of the trial is to determine whether the trial drug, zigakibart (also called FUB523), is safe and whether it can help people with IgA nephropathy (IgAN).